14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
BCAX vs TBPH: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Theravance Biopharma, Inc. (TBPH) is the stronger overall head-to-head candidate over Bicara Therapeutics Inc. (BCAX) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). BCAX carries a Unified Composite Score of 52.1/100 (HOLD) at $9.75 (N/M Forward P/E, 0.0% operating margin), whereas TBPH carries 54.9/100 (HOLD) at $17.03 (13.4x Forward P/E, 8.9% operating margin).
Growth vs. Quality Trade-Off: TBPH earns the overall head-to-head edge with a stronger Unified Composite Score (54.9/100 HOLD vs. BCAX 52.1/100 HOLD) and 0.48β · 2% Vol risk profile, whereas BCAX leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates.
Technical & Structure Timing Caution: BCAX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 32.7); meanwhile TBPH trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 53.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on BCAX vs TBPH. Trailing 12-month operating profitability (BCAX 0.0% vs TBPH 8.9%) and valuation multiples (BCAX N/M vs TBPH 13.4x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $884.2M market capitalization and 8.9% operating margin.
OpEx & R&D Reinvestment66.2% of Rev ($69M)
90D Engineering Disclosures0 Published
Investor FAQ BCAX vs TBPH Key Questions & Quantitative Answers
As of Nov 16, 2026, Theravance Biopharma, Inc. (TBPH) is the stronger overall head-to-head candidate over Bicara Therapeutics Inc. (BCAX) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). BCAX carries a Unified Composite Score of 52.1/100 (HOLD) at $9.75 (N/M Forward P/E, 0.0% operating margin), whereas TBPH carries 54.9/100 (HOLD) at $17.03 (13.4x Forward P/E, 8.9% operating margin). Growth vs. Quality Trade-Off: TBPH earns the overall head-to-head edge with a stronger Unified Composite Score (54.9/100 HOLD vs. BCAX 52.1/100 HOLD) and 0.48β · 2% Vol risk profile, whereas BCAX leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: BCAX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 32.7); meanwhile TBPH trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 53.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
TBPH leads the Growth & Scale pillar: BCAX posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with TBPH at -20.9% YoY revenue growth and +0.0% YoY earnings growth on $104M TTM revenue (75.1% gross margin, 8.9% operating margin). On trailing 12-month operating scale, BCAX generates N/A in USD-normalized revenue versus $104M for TBPH. In operating R&D and SG&A reinvestment, BCAX deploys N/A (0 90-day corporate R&D disclosures) versus 66.2% of Rev ($69M) (0 disclosures) for TBPH.
TBPH screens cheaper on headline valuation multiples. BCAX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas TBPH trades at 13.4x Forward P/E, 16.4x Trailing P/E, N/M PEG, and 8.5x EV/Revenue (10.6% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BCAX (-54.2% ROE) versus TBPH (20.9% ROE) capital efficiency.
In options market volatility and institutional positioning, BCAX carries 102.7% implied volatility (23rd %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.42β · 184% Vol realized risk). By comparison, TBPH carries 55.0% implied volatility (16th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.48β · 2% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.